<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00971048</url>
  </required_header>
  <id_info>
    <org_study_id>828-101-09-013</org_study_id>
    <nct_id>NCT00971048</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds</brief_title>
  <official_title>Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healthpoint</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Healthpoint</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare HP828-101 to standard of care for the management of partial or full thickness
      wounds
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to compare HP828-101 to standard of care for the management of
      partial or full thickness wounds, evaluated using the Bates Jensen Wound Assessment Tool
      (BWAT).

      The secondary objectives are comparison of the proportion of subjects with wound closure by
      day 22, comparison of pain assessed using a visual analog scale (VAS), and evaluation of
      moist wound environment as per the BWAT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adequate Management of the Wound Assessed by a Left Movement (Improvement) in the Modified Bates Jensen Wound Assessment Tool.</measure>
    <time_frame>22 - 29 days</time_frame>
    <description>Modified Bates-Jensen Wound Assessment (BWAT-m) Scores for those characteristics measured (wound size, depth, edges, undermining, necrotic tissue type and amount, exudate type and amount, periwound color and edema, granulation tissue, and epithelialization) were each graded on a 5-point scale, with 1 being the best and 5 being the worst.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Wound Closure by Day 22.</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Assessed by a 100-mm VAS Scale.</measure>
    <time_frame>At every visit: Day 8, Day 15, Day 22, Day 29</time_frame>
    <description>100-mm VAS scale was used to evaluate pain, with 1 being healthy tissue (no pain) up to 100 (wound degeneration and severe pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moist Wound Environment as Per the Bates-Jensen Wound Assessment Tool (BWAT)</measure>
    <time_frame>At every visit: Day 8, Day 15, Day 22, Day 29</time_frame>
    <description>Modified Bates-Jensen Wound Assessment (BWAT-m) Scores for those characteristics measured (wound exudate type and amount) were each graded on a 5-point scale, with 1 being the best and 5 being the worst.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <condition>Pressure Ulcers</condition>
  <arm_group>
    <arm_group_label>HP828-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For DFU SoC is a hydrogel. For PU SoC is a hydrocolloid gel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HP828-101</intervention_name>
    <description>Topical test article applied once daily</description>
    <arm_group_label>HP828-101</arm_group_label>
    <other_name>New device, no brand name identified-Code name is HP828-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrogel/Hydrocolloid</intervention_name>
    <description>Hydrogel for DFU and Hydrocolloid for PU (3M Tegaderm Hydrogel for DFU; ConvaTec DuoDERM Hydroactive Gel for PU); Topical test articles applied once daily</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>3M Tegaderm Hydrogel for DFU</other_name>
    <other_name>ConvaTec DuoDERM Hydroactive Gel for PU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The informed consent document must be read, signed, and dated by the subject or the
             subject's legally authorized representative before conducting any study procedures or
             exams. In addition, the informed consent document must be signed and dated by the
             individual who consents the subject before conducting Visit 1. A photocopy of the
             signed informed consent document must be provided to the subject, and the original
             signed document placed in the subject's chart. For subjects that agree to have their
             wound photographed for the trial, a photo release consent form must be signed and
             documented as well.

          -  Age 18 years or older, of either sex, and of any race or skin type, provided that
             their skin color, in the opinion of the Investigator, will not interfere with the
             study assessments.

          -  Females, if of child-bearing potential, have a negative urine pregnancy test and agree
             to use acceptable contraception during the study. Adequate birth control methods are
             defined as: hormonal—topical, oral, implantable, or injectable contraceptives;
             mechanical—spermicide in conjunction with a barrier such as a condom or diaphragm;
             IUD; or surgical sterilization of partner.

          -  Have a partial or full thickness PU on the foot or ankle or DFU of &lt;= 6 months
             duration and between ≥1.0 and ≤ 12.0 cm² in area.

          -  Are willing to make all required study visits.

          -  Are willing to follow instructions, in the opinion of the Investigator.

          -  Have, within 12 weeks prior to randomization, a serum albumin level ≥ 2.0 g/dL (20
             g/L); Alkaline phosphatase, AST, ALT, serum creatinine, and BUN levels &lt; 3 x upper
             limit of normal; HbA1C ≤ 12%; and Hemoglobin &gt;= 8 g/dL. The most recently obtained
             value must be evaluated against these criteria. Please refer to Appendix 18.1.5

          -  Have arterial supply adequacy confirmed by an Ankle Brachial Index (ABI) &gt;= 0.7 and ≤
             1.1 or if the ABI is &gt; 1.1, either a TcPO2 &gt;= 40 mmHg, as measured on the foot, or
             great toe pressure ≥ 50 mm/Hg,

          -  For ulcers that will require surgical debridement prior to enrollment, the wound must
             be expected to remain a partial thickness wound after debridement.

        Exclusion Criteria:

          -  Have a known hypersensitivity to any of the test articles or their components.

          -  Have received therapy with another investigational agent within thirty (30) days of
             Visit 1.

          -  Are pregnant or nursing.

          -  Have clinical evidence of bacterial or fungal infection of the wound per
             visual/clinical assessment.

          -  Have a severe burn, immunodeficiency disorder, hematologic disorder, or metastatic
             malignancy.

          -  Have had documented osteomyelitis on the target ulcer leg within 6 months preceding
             the screening visit.

          -  Have severe edema of the target ulcer leg.

          -  If being treated with Xenaderm, must stop treatment prior to enrolling in the study.

          -  Have received treatment with glucocorticoids for &gt; 10 consecutive days within 6 months
             prior to the start of the study.

          -  Have received chemotherapy or radiation therapy within the past 5 years.

          -  Therapy of the target ulcer with tissue-engineered cell-based skin equivalents within
             30 days preceding the Screening Visit (e.g., Apligraf®).

          -  Therapy of the target ulcer with topical growth factors within 1 week preceding the
             Screening Visit.

          -  Current therapy with systemic or topical antibiotics or systemic therapy with
             cytotoxic drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Innes Cargill, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Healthpoint, Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trovare Clinical Research</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Absolute Foot Care</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roy Kroeker</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Medical Technologies</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle Associates of Florida</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weil Foot and Ankle Institute</name>
      <address>
        <city>Des Plaines</city>
        <state>Illinois</state>
        <zip>60016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prigoff-Bowers LLP</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard Galperin, DPM</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Wunderlich, DPM</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dixie Regional Wound Clinic</name>
      <address>
        <city>St. George</city>
        <state>Utah</state>
        <zip>84770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ovington LG. The evolution of wound management: ancient origins and advances of the past 20 years. Home Healthc Nurse. 2002 Oct;20(10):652-6.</citation>
    <PMID>12394337</PMID>
  </reference>
  <reference>
    <citation>Winter GD. Formation of the scab and the rate of epithelisation of superficial wounds in the skin of the young domestic pig. 1962. J Wound Care. 1995 Sep;4(8):366-7; discussion 368-71.</citation>
    <PMID>7553187</PMID>
  </reference>
  <reference>
    <citation>HINMAN CD, MAIBACH H. EFFECT OF AIR EXPOSURE AND OCCLUSION ON EXPERIMENTAL HUMAN SKIN WOUNDS. Nature. 1963 Oct 26;200:377-8.</citation>
    <PMID>14087904</PMID>
  </reference>
  <reference>
    <citation>Andersen CA, Roukis TS. The diabetic foot. Surg Clin North Am. 2007 Oct;87(5):1149-77, x. Review.</citation>
    <PMID>17936480</PMID>
  </reference>
  <reference>
    <citation>Frykberg RG. Epidemiology of the diabetic foot: ulcerations and amputations. Adv Wound Care. 1999 Apr;12(3):139-41. Review.</citation>
    <PMID>10655794</PMID>
  </reference>
  <reference>
    <citation>Sussman C, Bates-Jensen B. Wound Care - A Collaborative Practice Manual for Health Professionals. 3rd Ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2006.</citation>
  </reference>
  <reference>
    <citation>Hess CT. Wound Care. 5th Ed ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2005.</citation>
  </reference>
  <reference>
    <citation>Steed DL, Attinger C, Colaizzi T, Crossland M, Franz M, Harkless L, Johnson A, Moosa H, Robson M, Serena T, Sheehan P, Veves A, Wiersma-Bryant L. Guidelines for the treatment of diabetic ulcers. Wound Repair Regen. 2006 Nov-Dec;14(6):680-92.</citation>
    <PMID>17199833</PMID>
  </reference>
  <reference>
    <citation>Agren MS. An amorphous hydrogel enhances epithelialisation of wounds. Acta Derm Venereol. 1998 Mar;78(2):119-22.</citation>
    <PMID>9534889</PMID>
  </reference>
  <reference>
    <citation>Whitney J, Phillips L, Aslam R, Barbul A, Gottrup F, Gould L, Robson MC, Rodeheaver G, Thomas D, Stotts N. Guidelines for the treatment of pressure ulcers. Wound Repair Regen. 2006 Nov-Dec;14(6):663-79.</citation>
    <PMID>17199832</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2009</study_first_submitted>
  <study_first_submitted_qc>September 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2009</study_first_posted>
  <results_first_submitted>October 9, 2013</results_first_submitted>
  <results_first_submitted_qc>December 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2014</results_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pressure ulcers</keyword>
  <keyword>PU</keyword>
  <keyword>diabetic foot ulcers</keyword>
  <keyword>DFU</keyword>
  <keyword>Bates-Jensen Wound Assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Pressure Ulcer</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adults 18 years of age and older who had a DFU or PU on the foot that was a partial or full thickness wound</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>HP828-101 Treating DFU</title>
          <description>HP828-101 : Topical test article approximately the size of a nickel, applied once daily Treatment group had diabetic foot ulcers (DFU)</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care Treating DFU</title>
          <description>For diabetic foot ulcers (DFU) Standard of Care (SoC) is a hydrogel
Hydrogel for DFU (3M Tegaderm Hydrogel)</description>
        </group>
        <group group_id="P3">
          <title>HP828-101 Treating PU</title>
          <description>HP828-101 : Topical test article approximately the size of a nickel, applied once daily Treatment group had pressure ulcers (PU)</description>
        </group>
        <group group_id="P4">
          <title>Standard of Care Treating PU</title>
          <description>For Pressure Ulcers (PU) Standard of Care (SoC) was a hydrocolloid gel
Hydrocolloid for PU: Topical test articles applied once daily (ConvaTec DuoDERM Hydroactive Gel for PU)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HP828-101 Treating DFU</title>
          <description>HP828-101 : Topical test article applied once daily Treatment group had diabetic foot ulcers (DFU)</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care Treating DFU</title>
          <description>For diabetic foot ulcers (DFU) Standard of Care (SoC) is a hydrogel
Hydrogel for DFU(3M Tegaderm Hydrogel)</description>
        </group>
        <group group_id="B3">
          <title>HP828-101 Treating PU</title>
          <description>HP828-101 : Topical test article applied once daily Treatment group had pressure ulcers (PU)</description>
        </group>
        <group group_id="B4">
          <title>Standard of Care Treating PU</title>
          <description>For Pressure Ulcers (PU) Standard of Care (SoC) was a hydrocolloid gel
Hydrocolloid for PU: Topical test articles applied once daily (ConvaTec DuoDERM Hydroactive Gel for PU)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" spread="13.5"/>
                    <measurement group_id="B2" value="63.5" spread="10.4"/>
                    <measurement group_id="B3" value="61.3" spread="12.6"/>
                    <measurement group_id="B4" value="64.1" spread="17.0"/>
                    <measurement group_id="B5" value="62.6" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adequate Management of the Wound Assessed by a Left Movement (Improvement) in the Modified Bates Jensen Wound Assessment Tool.</title>
        <description>Modified Bates-Jensen Wound Assessment (BWAT-m) Scores for those characteristics measured (wound size, depth, edges, undermining, necrotic tissue type and amount, exudate type and amount, periwound color and edema, granulation tissue, and epithelialization) were each graded on a 5-point scale, with 1 being the best and 5 being the worst.</description>
        <time_frame>22 - 29 days</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>HP828-101 Treating DFU</title>
            <description>HP828-101 : Topical test article applied once daily Treatment group had diabetic foot ulcers (DFU)</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Treating DFU</title>
            <description>For diabetic foot ulcers (DFU) Standard of Care (SoC) is a hydrogel
Hydrogel for DFU(3M Tegaderm Hydrogel)</description>
          </group>
          <group group_id="O3">
            <title>HP828-101 Treating PU</title>
            <description>HP828-101 : Topical test article applied once daily Treatment group had pressure ulcers (PU)</description>
          </group>
          <group group_id="O4">
            <title>Standard of Care Treating PU</title>
            <description>For Pressure Ulcers (PU) Standard of Care (SoC) was a hydrocolloid gel
Hydrocolloid for PU: Topical test articles applied once daily (ConvaTec DuoDERM Hydroactive Gel for PU)</description>
          </group>
        </group_list>
        <measure>
          <title>Adequate Management of the Wound Assessed by a Left Movement (Improvement) in the Modified Bates Jensen Wound Assessment Tool.</title>
          <description>Modified Bates-Jensen Wound Assessment (BWAT-m) Scores for those characteristics measured (wound size, depth, edges, undermining, necrotic tissue type and amount, exudate type and amount, periwound color and edema, granulation tissue, and epithelialization) were each graded on a 5-point scale, with 1 being the best and 5 being the worst.</description>
          <population>Intent-to-Treat</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.28" spread="0.89"/>
                    <measurement group_id="O2" value="21.38" spread="0.85"/>
                    <measurement group_id="O3" value="20.94" spread="1.63"/>
                    <measurement group_id="O4" value="20.59" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.12" spread="0.98"/>
                    <measurement group_id="O2" value="18.71" spread="0.93"/>
                    <measurement group_id="O3" value="19.78" spread="1.67"/>
                    <measurement group_id="O4" value="17.28" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Wound Closure by Day 22.</title>
        <time_frame>22 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HP828-101 Treating DFU</title>
            <description>HP828-101 : Topical test article applied once daily Treatment group had diabetic foot ulcers (DFU)</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Treating DFU</title>
            <description>For diabetic foot ulcers (DFU) Standard of Care (SoC) is a hydrogel
Hydrogel for DFU(3M Tegaderm Hydrogel)</description>
          </group>
          <group group_id="O3">
            <title>HP828-101 Treating PU</title>
            <description>HP828-101 : Topical test article applied once daily Treatment group had pressure ulcers (PU)</description>
          </group>
          <group group_id="O4">
            <title>Standard of Care Treating PU</title>
            <description>For Pressure Ulcers (PU) Standard of Care (SoC) was a hydrocolloid gel
Hydrocolloid for PU: Topical test articles applied once daily (ConvaTec DuoDERM Hydroactive Gel for PU)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Wound Closure by Day 22.</title>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Assessed by a 100-mm VAS Scale.</title>
        <description>100-mm VAS scale was used to evaluate pain, with 1 being healthy tissue (no pain) up to 100 (wound degeneration and severe pain)</description>
        <time_frame>At every visit: Day 8, Day 15, Day 22, Day 29</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>HP828-101 Treating DFU</title>
            <description>HP828-101 : Topical test article applied approximately the size of a nickel, once daily Treatment group had diabetic foot ulcers (DFU)</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Treating DFU</title>
            <description>For diabetic foot ulcers (DFU) Standard of Care (SoC) is a hydrogel
Hydrogel for DFU(3M Tegaderm Hydrogel)</description>
          </group>
          <group group_id="O3">
            <title>HP828-101 Treating PU</title>
            <description>HP828-101 : Topical test article applied approximately the size of a nickel, once daily Treatment group had pressure ulcers (PU)</description>
          </group>
          <group group_id="O4">
            <title>Standard of Care Treating PU</title>
            <description>For Pressure Ulcers (PU) Standard of Care (SoC) was a hydrocolloid gel
Hydrocolloid for PU: Topical test articles applied once daily (ConvaTec DuoDERM Hydroactive Gel for PU)</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Assessed by a 100-mm VAS Scale.</title>
          <description>100-mm VAS scale was used to evaluate pain, with 1 being healthy tissue (no pain) up to 100 (wound degeneration and severe pain)</description>
          <population>Intent-to-Treat</population>
          <units>VAS Pain Scores</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.92" spread="1.84"/>
                    <measurement group_id="O2" value="4.85" spread="1.75"/>
                    <measurement group_id="O3" value="4.76" spread="1.21"/>
                    <measurement group_id="O4" value="6.99" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.09" spread="2.18"/>
                    <measurement group_id="O2" value="3.21" spread="2.07"/>
                    <measurement group_id="O3" value="3.49" spread="2.95"/>
                    <measurement group_id="O4" value="8.85" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.57" spread="2.90"/>
                    <measurement group_id="O2" value="3.6" spread="2.76"/>
                    <measurement group_id="O3" value="3.66" spread="3.50"/>
                    <measurement group_id="O4" value="6.63" spread="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.16" spread="2.41"/>
                    <measurement group_id="O2" value="1.53" spread="2.30"/>
                    <measurement group_id="O3" value="4.33" spread="2.36"/>
                    <measurement group_id="O4" value="8.70" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Moist Wound Environment as Per the Bates-Jensen Wound Assessment Tool (BWAT)</title>
        <description>Modified Bates-Jensen Wound Assessment (BWAT-m) Scores for those characteristics measured (wound exudate type and amount) were each graded on a 5-point scale, with 1 being the best and 5 being the worst.</description>
        <time_frame>At every visit: Day 8, Day 15, Day 22, Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HP828-101 Treating DFU</title>
            <description>HP828-101 : Topical test article applied approximately the size of a nickel, once daily Treatment group had diabetic foot ulcers (DFU)</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Treating DFU</title>
            <description>For diabetic foot ulcers (DFU) Standard of Care (SoC) is a hydrogel
Hydrogel for DFU(3M Tegaderm Hydrogel)</description>
          </group>
          <group group_id="O3">
            <title>HP828-101 Treating PU</title>
            <description>HP828-101 : Topical test article applied approximately the size of a nickel, once daily Treatment group had pressure ulcers (PU)</description>
          </group>
          <group group_id="O4">
            <title>Standard of Care Treating PU</title>
            <description>For Pressure Ulcers (PU) Standard of Care (SoC) was a hydrocolloid gel
Hydrocolloid for PU: Topical test articles applied once daily (ConvaTec DuoDERM Hydroactive Gel for PU)</description>
          </group>
        </group_list>
        <measure>
          <title>Moist Wound Environment as Per the Bates-Jensen Wound Assessment Tool (BWAT)</title>
          <description>Modified Bates-Jensen Wound Assessment (BWAT-m) Scores for those characteristics measured (wound exudate type and amount) were each graded on a 5-point scale, with 1 being the best and 5 being the worst.</description>
          <units>BWAT-m Exudate Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.14"/>
                    <measurement group_id="O2" value="1.90" spread="0.14"/>
                    <measurement group_id="O3" value="1.78" spread="0.20"/>
                    <measurement group_id="O4" value="2.43" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="0.14"/>
                    <measurement group_id="O2" value="1.88" spread="0.13"/>
                    <measurement group_id="O3" value="1.80" spread="0.25"/>
                    <measurement group_id="O4" value="1.95" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.17"/>
                    <measurement group_id="O2" value="1.77" spread="0.16"/>
                    <measurement group_id="O3" value="1.89" spread="0.32"/>
                    <measurement group_id="O4" value="2.24" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.14"/>
                    <measurement group_id="O2" value="1.51" spread="0.12"/>
                    <measurement group_id="O3" value="1.98" spread="0.37"/>
                    <measurement group_id="O4" value="2.02" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>29 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HP828-101 Treating DFU</title>
          <description>HP828-101 : Topical test article applied once daily Treatment group had diabetic foot ulcers (DFU)</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care Treating DFU</title>
          <description>For diabetic foot ulcers (DFU) Standard of Care (SoC) is a hydrogel
Hydrogel for DFU(3M Tegaderm Hydrogel)</description>
        </group>
        <group group_id="E3">
          <title>HP828-101 Treating PU</title>
          <description>HP828-101 : Topical test article applied once daily Treatment group had pressure ulcers (PU)</description>
        </group>
        <group group_id="E4">
          <title>Standard of Care Treating PU</title>
          <description>For Pressure Ulcers (PU) Standard of Care (SoC) was a hydrocolloid gel
Hydrocolloid for PU: Topical test articles applied once daily (ConvaTec DuoDERM Hydroactive Gel for PU)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection of ulcer - nontarget ulcer</sub_title>
                <description>The severity of the event was Moderate; the Investigator determined that the serious adverse event was not related to the test article. Subject discontinued from the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Study drug dosage was interrupted during the hospitalization. The severity of the event was Moderate; the Investigator determined that the SAE was not related to the test article. Subject discontinued from the study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>The severity of the event was Mild; the Investigator determined that the serious adverse event was not related to the test article. Subject completed the study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jaime Dickerson, PhD</name_or_title>
      <organization>Smith &amp; Nephew Biotherapeutics</organization>
      <phone>817-302-3914</phone>
      <email>jaime.dickerson@smith-nephew.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

